医疗大麻在线供应商MOCA（Medicinal Organic Cannabis Australia）承认其产品被错误宣传为获得澳大利亚治疗用品管理局（TGA）批准，并已删除相关网页声明1。然而该公司表示仅会考虑是否通知现有客户此项变化1。SBS新闻调查发现，多家诊所使用误导性措辞暗示其大麻产品已获TGA批准1。
根据澳大利亚注册治疗用品清单（ARTG），目前仅有两种获批的大麻药物——Epidyolex和Sativex——正式列入1。超过99%的澳大利亚医疗大麻产品未列入ARTG，未经TGA评估其安全性、质量或有效性1。TGA指出，《治疗用品法1989》明确禁止在广告中暗示治疗用品已获政府或政府部门的批准或推荐1。澳大利亚皇家全科医生学会（RACGP）已就此提交意见，要求改革医疗大麻的处方和监管方式1。
Medicinal Organic Cannabis Australia (MOCA), an online supplier of therapeutic cannabis, has removed misleading claims from its website asserting that its products were approved by the Therapeutic Goods Administration (TGA), but has indicated it will only "consider" whether to inform existing customers of these changes.1
An SBS News investigation revealed that MOCA's website previously stated its complete product range—including capsules, sublingual oils, isolates, vaporizer pens, and whole cannabis flower—had received TGA approval.1 In reality, more than 99% of medicinal cannabis products in Australia lack TGA approval and have not been evaluated for safety, quality, or efficacy.1 The Australian Register of Therapeutic Goods (ARTG) lists only two approved cannabis medications: Epidyolex and Sativex, which together account for less than 1% of all medicinal cannabis products in the country.1
The investigation identified multiple clinics using similarly misleading language to suggest their cannabis products had secured government endorsement.1 The TGA has stated that the Therapeutic Goods Act 1989 prohibits advertising that implies therapeutic products have received government or government department approval or recommendation.1 Additionally, the Royal Australian College of General Practitioners (RACGP) has submitted advocacy for reform to how medicinal cannabis prescribing and regulation operate in the country.1
评论
还没有评论，欢迎留下第一条。